High-dose busulfan and the risk of pulmonary mortality after autologous stem cell transplant

Clinical Transplantation

Volumn 20, Issue 6, 2006, Pages 783-787

  Kalaycio, Matt ^a   Pohlman, Brad ^a   Kuczkowski, Elizabeth ^a   Rybicki, Lisa ^a   Andresen, Steve ^a   Sobecks, Ronald ^a   Bolwell, Brian ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Autologous stem cell transplant; Busulfan; Pulmonary toxicity

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGE; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG MEGADOSE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INCIDENCE; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LUNG COMPLICATION; LUNG INSUFFICIENCY; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PNEUMONIA; PRIORITY JOURNAL; RISK ASSESSMENT;

ADOLESCENT; ADULT; AGED; BUSULFAN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 33750810422     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2006.00581.x     Document Type: Article

References (18)

1. Bolwell BJ. Autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Semin Oncol 1994: 21: 86.
2. Sheridan WP, Begley CG, Juttner CA et.al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992: 339: 640.
3. Nemunaitis J, Rabinowe SN, Singer JW et.al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. New Engl J Med 1991: 324: 1773.
4. Wheeler C, Khurshid A, Ibrahim J et.al. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). Leuk Lymphoma 2001: 40: 499.
5. Hosing C, Munsell M, Yazji S et.al. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol 2002: 13: 450.
6. Fassas AB, Tricot G. Myelodysplastic syndromes complicating hematopoietic stem cell transplantation. Cancer Treat Res 2001: 108: 169.
7. Alessandrino EP, Bernasconi P, Colombo A et.al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant 2000: 25: 309.
8. Wilczynski SW, Erasmus JJ, Petros WP, Vredenburgh JJ, Folz RJ. Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer. Am J Respir Crit Care Med 1998: 157: 565.
9. Copelan EA, Penza SL, Pohlman B et.al. Autotransplantation following busulfan, etoposide, and cyclophosphamide in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2000: 25: 1243.
10. Oakhill A, Green I, Knowlson G. Busulphan lung in childhood. J Clin Pathol 1981: 34: 495.
11. Burns WA, Mc Farland W, Matthews MJ. Busulfan-induced pulmonary disease. Am Rev Respir Dis 1968: 101: 408.
12. Kalaycioglu M, Kavuru M, Tuason L, Bolwell B. Empiric prednisone therapy for pulmonary toxic reaction after high-dose chemotherapy containing carmustine (BCNU). Chest 1995: 107: 482.
13. Kalaycioglu M, Lichtin AE, Andresen SW, Tuason L, Bolwell B. High-dose busulfan and cyclophosphamide followed by autologous bone marrow and/or peripheral blood progenitor cell rescue for metastatic breast cancer. Am J Clin Oncol 1995: 18: 491.
14. Gopal AK, Gooley TA, Golden JB et.al. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Bone Marrow Transplant 2001: 27: 593.
15. Bolwell BJ. Are predictive factors clinically useful in bone marrow transplantation? Bone Marrow Transplant 2003: 32: 853.
16. Jain B, Floreani AA, Anderson JR et.al. Cardiopulmonary function and autologous bone marrow transplantation: Results and predictive value for respiratory failure and mortality. The University of Nebraska Medical Center Bone Marrow Transplantation Pulmonary Study Group. Bone Marrow Transplant 1996: 17: 561.
17. Crawford SW, Hackman RC. Clinical course of idiopathic pneumonia after bone marrow transplantation. Am Rev Respir Dis 1993: 147: 1393.
18. Bhalla KS, Wilczynski SW, Abushamaa AM et.al. Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support. Am J Respir Crit Care Med 2000: 161: 17.